辅助CDK4/6抑制剂时代假体重建和乳房切除术后放疗的并发症

IF 1.6 4区 医学 Q4 ONCOLOGY
Hamail Iqbal, Badal Juneja, Sophia Chryssofos, Stuti Ahlawat, Steven Bonawitz, A Leilani Fahey, Catherine Loveland-Jones, Leah Steinmetz, Danny Markabawi, Christine Kurian, Anthony E Dragun
{"title":"辅助CDK4/6抑制剂时代假体重建和乳房切除术后放疗的并发症","authors":"Hamail Iqbal, Badal Juneja, Sophia Chryssofos, Stuti Ahlawat, Steven Bonawitz, A Leilani Fahey, Catherine Loveland-Jones, Leah Steinmetz, Danny Markabawi, Christine Kurian, Anthony E Dragun","doi":"10.1097/COC.0000000000001186","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Abemaciclib is approved for adjuvant use in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Its toxicity profile is derived from studies favoring patients undergoing breast conservation therapy. This study investigates the impact of abemaciclib on wound complications in the setting of postmastectomy radiation therapy (PMRT) and implant-based reconstruction.</p><p><strong>Methods: </strong>A single-center, retrospective chart review was conducted. Patients who underwent mastectomy, implant-based reconstruction, and PMRT between January 2020 and December 2022 were included. Descriptive statistics characterized the study population and determined rates of any complication, major complications requiring reoperation, and complications by subtype (contracture, extrusion, tissue expander changes, infection, seroma, dermatitis, and pain). χ2 and the Fisher Exact tests assessed associations between abemaciclib use, complications, and potential risk factors.</p><p><strong>Results: </strong>Seventy-five patients were included. Fifteen underwent adjuvant abemaciclib therapy. Thirty-four patients (45.3%) were obese (BMI ≥30), 24 (32.0%) had a smoking history, and 4 (5.3%) had diabetes. The incidences of any complication and major complications were 33.3% and 17.5%, respectively. There was no significant association between abemaciclib use and any complication (P=1.000), major complications (P=0.729), or any complication subtype (P=0.865). There was a significant association between BMI and any complication (P=0.014).</p><p><strong>Conclusions: </strong>The study suggests that the use of adjuvant abemaciclib is not associated with an increased risk of postradiation reconstructive complications in patients undergoing implant-based reconstruction. Continued surveillance of complications associated with abemaciclib is warranted with a larger sample size.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":"48 7","pages":"357-361"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complications of Implant-Based Reconstruction and Postmastectomy Radiation in the Era of Adjuvant CDK4/6 Inhibitors.\",\"authors\":\"Hamail Iqbal, Badal Juneja, Sophia Chryssofos, Stuti Ahlawat, Steven Bonawitz, A Leilani Fahey, Catherine Loveland-Jones, Leah Steinmetz, Danny Markabawi, Christine Kurian, Anthony E Dragun\",\"doi\":\"10.1097/COC.0000000000001186\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Abemaciclib is approved for adjuvant use in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Its toxicity profile is derived from studies favoring patients undergoing breast conservation therapy. This study investigates the impact of abemaciclib on wound complications in the setting of postmastectomy radiation therapy (PMRT) and implant-based reconstruction.</p><p><strong>Methods: </strong>A single-center, retrospective chart review was conducted. Patients who underwent mastectomy, implant-based reconstruction, and PMRT between January 2020 and December 2022 were included. Descriptive statistics characterized the study population and determined rates of any complication, major complications requiring reoperation, and complications by subtype (contracture, extrusion, tissue expander changes, infection, seroma, dermatitis, and pain). χ2 and the Fisher Exact tests assessed associations between abemaciclib use, complications, and potential risk factors.</p><p><strong>Results: </strong>Seventy-five patients were included. Fifteen underwent adjuvant abemaciclib therapy. Thirty-four patients (45.3%) were obese (BMI ≥30), 24 (32.0%) had a smoking history, and 4 (5.3%) had diabetes. The incidences of any complication and major complications were 33.3% and 17.5%, respectively. There was no significant association between abemaciclib use and any complication (P=1.000), major complications (P=0.729), or any complication subtype (P=0.865). There was a significant association between BMI and any complication (P=0.014).</p><p><strong>Conclusions: </strong>The study suggests that the use of adjuvant abemaciclib is not associated with an increased risk of postradiation reconstructive complications in patients undergoing implant-based reconstruction. Continued surveillance of complications associated with abemaciclib is warranted with a larger sample size.</p>\",\"PeriodicalId\":50812,\"journal\":{\"name\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"volume\":\"48 7\",\"pages\":\"357-361\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Oncology-Cancer Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COC.0000000000001186\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001186","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/5 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:Abemaciclib被批准用于激素受体阳性、人表皮生长因子受体2阴性的乳腺癌的辅助治疗。它的毒性来自于对接受乳房保护治疗的患者有利的研究。本研究探讨abemaciclib对乳房切除术后放射治疗(PMRT)和种植体重建中伤口并发症的影响。方法:采用单中心回顾性图表分析。纳入了2020年1月至2022年12月期间接受乳房切除术、基于植入物的重建和PMRT的患者。描述性统计描述了研究人群的特征,并确定了任何并发症、需要再次手术的主要并发症和并发症亚型(挛缩、挤压、组织扩张器改变、感染、血肿、皮炎和疼痛)的发生率。χ2和Fisher Exact检验评估了abemaciclib使用、并发症和潜在危险因素之间的关联。结果:纳入75例患者。15例接受了阿贝马昔单抗辅助治疗。肥胖(BMI≥30)34例(45.3%),有吸烟史24例(32.0%),糖尿病4例(5.3%)。所有并发症和主要并发症的发生率分别为33.3%和17.5%。使用abemaciclib与任何并发症(P=1.000)、主要并发症(P=0.729)或任何并发症亚型(P=0.865)均无显著相关性。BMI与并发症有显著相关性(P=0.014)。结论:该研究表明,在接受植体重建的患者中,使用辅助abemaciclib与术后重建并发症的风险增加无关。继续监测与abemaciclib相关的并发症需要更大的样本量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Complications of Implant-Based Reconstruction and Postmastectomy Radiation in the Era of Adjuvant CDK4/6 Inhibitors.

Objectives: Abemaciclib is approved for adjuvant use in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Its toxicity profile is derived from studies favoring patients undergoing breast conservation therapy. This study investigates the impact of abemaciclib on wound complications in the setting of postmastectomy radiation therapy (PMRT) and implant-based reconstruction.

Methods: A single-center, retrospective chart review was conducted. Patients who underwent mastectomy, implant-based reconstruction, and PMRT between January 2020 and December 2022 were included. Descriptive statistics characterized the study population and determined rates of any complication, major complications requiring reoperation, and complications by subtype (contracture, extrusion, tissue expander changes, infection, seroma, dermatitis, and pain). χ2 and the Fisher Exact tests assessed associations between abemaciclib use, complications, and potential risk factors.

Results: Seventy-five patients were included. Fifteen underwent adjuvant abemaciclib therapy. Thirty-four patients (45.3%) were obese (BMI ≥30), 24 (32.0%) had a smoking history, and 4 (5.3%) had diabetes. The incidences of any complication and major complications were 33.3% and 17.5%, respectively. There was no significant association between abemaciclib use and any complication (P=1.000), major complications (P=0.729), or any complication subtype (P=0.865). There was a significant association between BMI and any complication (P=0.014).

Conclusions: The study suggests that the use of adjuvant abemaciclib is not associated with an increased risk of postradiation reconstructive complications in patients undergoing implant-based reconstruction. Continued surveillance of complications associated with abemaciclib is warranted with a larger sample size.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
130
审稿时长
4-8 weeks
期刊介绍: ​​​​​​​American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信